(Q44004071)

28 November 2017

0 references

Niacin: the only vitamin that reduces cardiovascular events (English)

1 reference

28 November 2017

1 reference

1 reference

A S Wierzbicki

1

1 reference

28 November 2017

1 April 2011

1 reference

International Journal of Clinical Practice

28 November 2017

1 reference

28 November 2017

65

1 reference

28 November 2017

4

1 reference

28 November 2017

379-385

1 reference

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

28 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

HDL-c is a powerful lipid predictor of cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

FIELDS of dreams, fields of tears: a perspective on the fibrate trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Fibrates: no ACCORD on their use in the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Nicotinic acid: pharmacological effects and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Calcitonin gene-related peptide, adrenomedullin and flushing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

The role of nicotinic acid metabolites in flushing and hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Systems biology approaches and pathway tools for investigating cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

Differences in metabolism of time-release and unmodified nicotinic acid: Explanation of the differences in hypolipidemic action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02630.X

10.1111/J.1742-1241.2011.02630.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference

PubMed ID

21401825